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The present results do not support the theory of increased
synthesis of renal venopressor PGF.. in black hypertensive
patients.
Further studies are necessary to confirm the possibility of
ethnic pattern in renal PG synthesis.
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Duchenne and Becker
muscular dystrophy
prevalence in South Africa
and molecular findings in
128 persons affected
R. Ballo, D. Viljoen, P. Beighton
A genetic service for Duchenne muscular dystrophy (DMD)
and Becker muscular dystrophy (BMD) was initiated in
Cape Town in 1987. Of the 143 DMD patients diagnosed
during the period 1987-1992, 66 had a familial pattern of
inheritance and 77 were apparently sporadic. Twenw BMD
patients were identified, of whom 12 had other affected
relatives and 8 were sporadic. Overall minimum
prevalence rates of 1/100 000 for DMD and 1n55 000 for
BMD were calculated. A markedly low DMD prevalence in
the indigenous black population (1/250000) contributed to
the overall low DMD prevalence in South Africa when
compared with that in the UK (1/40 000).
By means of molecular methods, the diagnosis in 42%
of the affected DMD males was confirmed by detection of
deletions in the dystrophin gene. Deletions were identified
in 50% of Indian, white and mixed ancestry patients. In
contrast, only 22% of blacks had identifiable deletions.
DMD appears to be underrepresented in the black
population; the low deletion frequency in this group
suggests that unique mutations not detectable by
methods used in this study may be more frequent in these
patients than in the other populations. The increased DMD
frequency in Indians corroborates findings reported from
the UK.
S Afr Med J 1994; 84: 494-497.
Duchenne muscular dystrophy (DMD) is the most common
heritable muscle disorder' and is transmitted as an X-linked
recessive trait. Affected boys characteristically exhibit
progressive muscle weakness and pseudohypertrophy of the
calf muscles! The disorder .has an inexorable progressive
clinical course culminating in death in the teenage years. A
similar but milder condition, Becker muscular dystrophy
(BMD), occurs less commonly. Those with this disorder are
less severely affected and are usually able to procreate.3
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The diagnosis of DMD or BMD is suggested by their
typical clinical presentation in males and can be confirmed
by demonstration of raised muscle serum enzyme levels
together with histological findings in muscle biopsy
specimens. In addition, molecular techniques now allow
exact identification of mutations in the gene which is located
on the short arm of the X-chromosome (Xp21).'
A previous article provided details of a national molecular
genetics service for the diagnosis of DMD/ BMD based at
the Department of Human Genetics molecular laboratory in
Cape Town.. The relative prevalences of DMD are
remarkably dissimilar in different ethnic groups in South
Africa, as are the intragenic molecular defects.
The implications of these findings for health care planning
and community-orientated genetics services form the basis
of this article.
Patients and methods
A national diagnostic service for DMD and BMD was
initiated in South Africa in 1987. Efforts were made to
identify affected boys by means of a letter circulated to
paediatricians, general practitioners, genetics nurses of the
Department of National Health and Population Development,
and physicians in charge of muscle/neurology clinics at
medical centres in all four provinces. Further information
was disseminated by medical articles in local journals and
through lectures, seminars and the presentation of papers at
medical congresses. In addition, rural populations were
screened at routine genetics clinics held in peripheral
centres throughout South Africa.
DMD and BMD were differentiated on the basis of age of
onset and wheelchair confinement, as described by Emery!
In all instances the clinical diagnosis was established by a
paediatrician or physician and confirmed by appropriate
ancillary investigations, including the findings of elevated
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serum creatine kinase levels. In some instances, the
diagnosis was established through histological studies
assisted by electromyography. Minimum prevalences for the
condition were calculated for the four major ethnic groups
found in South Africa on the basis of the number of living
affected males identified during the period 1987-1992
(Table I).
Blood specimens were collected from each patient, and
the DNA isolated for molecular analysis, as described
preViously.' The DNA was screened for intragenic deletions
with probes from hotspot areas in the 5' and 3' region of the
dystrophin gene.·" These investigations were supplemented
by DNA amplification technology such as oligonucleotide
primers which were specific for exons in the deletion-prone
regions. The frequencies of deletions identified in the various
ethnic groups are summarised in Table 11.
Results
A total of 143 DMD and 20 BMD patients were investigated
during 1987-1992. All the boys of Indian origin were referred
from Natal, whereas the majority of patients of mixed
ancestry (97%) were investigated in the Cape. About 40% of
the black patients were examined in Cape Town; the
remaining 60% were referred by clinicians from the other
provinces. The white referrals came from all parts of the
country. Of the 143 males with DMD, 66 had at least one
affected relative while 77 were sporadic. Twelve of the 20
patients with BMD had affected kin and 8 cases had
occurred sporadically.
Observed minimum prevalence for DMD varied for each
ethnic group, the highest prevalence occurring among the
Indian popUlation and the lowest among the black. Only 2
BMD patients were seen in each of the black, Indian and
mixed ancestry groups, whereas 14 affected white males
were studied.
Table I. Minimum prevalences calculated for DMD in South Africans of different ethnic origins
Male population Affected Minimum prevalence Affected Minimum prevalence
Ethnic group x 10.3 DMD of DMD x 10" BMD of BMD x 10.3




10700 43 1:250 2 1:5350




465 33 1:14 2 1:233




1570 13 1:45 2 1:785
-




2610 32 1:82 14 1:186
-- -- -- -
Total 15092 143 1:100 20 1:755
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Table 11. The frequency and distribution of deletions in the dystrophin gene of South African DMD and BMD patients
Deletions 5' 3' 5' - 3'
Ethnic group No. of unrelated patients No. % No. % No. % No. %
Black
DMD 39 10 26 3 30 5 50 2 20
BMD 2 0
White
DMD 23 13 57 4 31 9 68 0
BMD 9 3 44 2 1
Indian
DMD 21 10 45 2 20 8 80 0 0
BMD 3 2 67 1
Mixed ancestry
8 61 8DMD 27 13 48 4 31
BMD 4 1 25 1
Total
DMD 110 46 42 28 65 7
BMD 18 6 33 50 25 25
5' = 5' hotspot of DMD gene
3' = 3' hotspot of BMD gene
Deletion detection
Molecular investigations were undertaken in 110 males with
DMD and 18 with BMD. Deletions were detected in 46 (42%)
of the DMD patients and 6 (33%) of the BMD patients. More
than 60% of the DMD deletions occurred in the 3' region of
the dystrophin gene while the BMD deletions occurred
predominantly in the 5' region of the gene. Forty-five percent
to 60% of DMD patients from the white, Indian and mixed
ancestry groups had detectable deletions. Only 10 (26%) of
the black patients had detectable deletions.
Discussion
Minimum prevalence
The determination of DMD and BMD prevalences in South
Africa is necessarily incomplete for several reasons. Firstly,
because a significant proportion of the South African
population resides in rural areas, it is unlikely for logistic
reasons, that all those affected have been identified.
Estimates of population size based on census figures are
also probably an underrepresentation of the true situation in
South Africa. Also, some individuals had no knowledge of .
their family history, It is also possible that some sporadic
DMD patients may be misdiagnosed instances of the rare
but phenotypically similar autosomal recessive form of
muscular dystrophy.8,g
Minimum prevalence of DMD
Minimum prevalence estimates in the South African
population reveal a higher DMD frequency in Indians
(1/14000) compared with other ethnic populations
(1/45000 - 1/250 000). A possible explanation might be an
increased occurrence of the AR form of DMD in Indians. If
this were so, however, one would expect also to encounter a
significant proportion of affected females, which is not the
case. Interestingly, a high frequency of DMD in the Indian
population of the West Midlands region of the UK was
recently reported.,e It is therefore possible that there is a
genuine increased frequency of classic X-linked DMD in this
group. The frequency of DMD among patients of mixed
ancestry is less than that among Indians, but greater than
that of whites. The latter phenomenon possibly reflects
genetic admixture.
Since the black male population of South Africa is much
larger than that of any of the other ethnic groups (10,7
million v. 4,65 million for all others combined), the observed
number of black males affected was unexpectedly low.
Indeed, despite the urbanised black group served by good
hospital facilities (e.g. Red Cross Children's Hospital in Cape
Town, King Edward VIII Hospital in Durban and Medunsa in
Pretoria), DMD patient numbers remained low. In this
context, it is noteworthy that adverse socio-economic
circumstances have not prevented black mothers from
having their children investigated for other muscular
disorders, e.g. spinal muscular atrophy is 15 times more
prevalent than DMD in the South African black population
(A. Moosa - personal communication). The latter evidence
suggests that a black mother usually seeks professional
help for any child with a progressive physical handicap such
as DMD. The observed decreased frequency of DMD may
therefore reflect a true underrepresentation of the disorder in
the indigenous black population of South Africa.
Minimum prevalence of BMD
The overall BMD prevalence observed in this study (and in
other parts of the world) is much lower (1/755000)
compared with recently published figures from the UK." This
apparent underrepresentation of BMD is probably caused by
incomplete ascertainment as a result of lack of recognition
of the milder disorders. In this regard, analysis of the protein
product, dystrophin, allows BMD to be accurately
distinguished from clinically similar muscle disorders such as
spinal muscular atrophy and limb girdle dystrophy.
Interestingly, the range of clinical manifestations observed
in patients with BMD is now extensive, e.g. a condition
known as 'myalgia with cramps' has been identified by
means of molecular studies as a mild form of BMD."
Accurate BMD prevalence estimations therefore require
dystrophin analysis in all patients with suggestive clinical
signs,
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Molecular findings
A total of 46 (42%) deletions were identified in 110 unrelated
South African DMD patients. This deletion frequency is
consistent with published values of 40 - 60% in other
populations, where a similar methodology was used.'2.'s Of
the 46 deletions detected in the present study, 65% had a
breakpoint in the 3' mutation 'hotspot' whereas only 28%
were detected in the 5' 'hotspot'. This distribution
corroborates previous reports.'··" However, although the
deletion frequency and distribution in South African patients
are similar to those in patients reported elsewhere,
considerable inter-ethnic variation is apparent. The low rate
of deletions in black patients (less than 30%) might be due
to other intragenic mutations lying outside the known
deletion hotspots. The phenotype in those black patients in
whom deletions were not detected is identical to that in
other groups and non-allelic heterogeneity seems unlikely.
It would therefore appear that intragenic deletions for
DMD/BMD among blacks occur less frequently and may
differ from those previously described in whites.
The low prevalence of DMD and BMD observed in black
South Africans remains an enigma but is in keeping with
findings elsewhere. It is probable, given the wide but mild
spectrum of clinical manifestations of BMD, that many
patients do not seek medical appraisal. Previously
underscribed point mutations and deletions are likely to be
discovered in some affected black patients. Studies to
elucidate these anomalies at the molecular level are
currently underway.
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Aspects of Roaccutane
prescription in South Africa
A. J. Smart, L. Waiters
A nationwide postmarketing surveillanc-e study on the use
and outcomes of use of isotretinoin has been conducted
in South Africa A representative sample of prescribers of
the drug was identified from drug utilisation data and the
overall doctor response rate was 90,1 %. A total of 766
patients was enrolled in the study, of which 728 were
analysable for safety and efficacy. More than half the
patients prescribed isotretinoin were women, of whom
only 48,25% were practising some form of contraception.
The mean overall dosage prescribed was 0,64 mg/kg/day
and the mean overall duration of therapy prescribed was
15,5 weeks. The mean dose and duration of therapy
prescribed by dermatologists was significantly higher than
that prescribed by general practitioners. Potentially
dangerous drug interactions involving the concomitant use
of isotretinoin with tetracyclines, vitamin A and oral
contraceptives together with antibiotics were noted.
Mucocutaneous drying effects were the most common
adverse events and the incidence of these effects
decreased with continuation of therapy. The known
effectiveness of the drug was confirmed by the results of
the study.
S Afr Med J 1994; 84: 497-502.
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